Tamtam Try Tamtam free
Gerresheimer logo

Gerresheimer account plan

Drug delivery solutions manufacturing

At a glance

Gerresheimer is a Düsseldorf maker of drug containment and delivery products for pharma, with FY2025 revenues of EUR 2,320.9m and about 13,600 people.

Gerresheimer AG, based in Düsseldorf, supplies the pharmaceutical, biotech and cosmetics industries with drug containment and delivery products: syringes, pens, auto-injectors, inhalers, injection vials, cartridges, ampoules and plastic and glass bottles. It produces locally in Europe, the Americas and Asia, with companies consolidated from 17 countries and approximately 13,600 people at November 30, 2025. FY2025 (year to November 30, 2025) revenues were EUR 2,320.9m, lifted by the first-time inclusion of Bormioli Pharma, with adjusted EBITDA of EUR 384.0m (16.5% margin) and a net loss of EUR 318.7m. After a BaFin audit led to a restatement of 2024 accounts, the whole Management Board changed; CFO Wolf Lehmann and board member Achim Schalk now lead as co-CEOs pending a permanent CEO.

Business units

Strategic priorities

Deleverage and refinance
Centor closed on October 1, 2026, with about 90% of gross proceeds going to debt and close to EUR 700 million repaid by year-end; after the Primary Packaging Plastics closing, leverage should fall to around 3x and a comprehensive refinancing follow.
Grow, fix, sell portfolio
Grow Medical Device Systems, Syringe Systems and Tubular Glass North America; fix Tubular Glass Europe and SG&A; fix to sell Moulded Glass.
Gerresheimer Transformation Offensive (gto)
Launched September 2025 with five workstreams (Operations, SG&A, Procurement, Commercial Excellence, Cash Management), targeting EUR 50-70 million of annualized EBITDA improvement by end-2027 and full run rate in 2028.
Leaner cost base and footprint
SG&A is to be cut by more than 20% heading into 2027; Bad Königshofen and Chicago Heights are closed and Forest Grove is being merged into Morganton.
Drug delivery and GLP-1 growth
Peachtree revenue is expected to more than double in FY2026 to a triple-digit million euro level, and GLP-1 revenue is in the ballpark of the EUR 350 million target, backed by take-or-pay contracts.
Governance clean-up
The new board completed the bill-and-hold and forensic investigations, increased Internal Audit and Compliance staffing and continues to cooperate with the ongoing BaFin investigation.

Latest results

Preliminary Q3 2026 (June-August 2026) revenue rose 8% to EUR 605 million, with adjusted EBITDA stable at EUR 103 million (EUR 106 million) and a 17.1% margin (19.0%). Over nine months revenue was flat at EUR 1.7 billion and adjusted EBITDA fell to EUR 272 million (EUR 331 million), hit by inventory reductions and weak Tubular Glass Europe and Moulded Glass. Q3 free cash flow before M&A was EUR -20 million. FY2026 guidance was kept at revenue of EUR 2.3-2.35 billion, an organic adjusted EBITDA margin of 17%-18% and free cash flow of EUR -50 to -100 million, which requires around EUR 120 million of Q4 EBITDA.

Investments and deals

Centor and PPP divestments
Centor and Primary Packaging Plastics were signed at the end of July 2026 at a combined enterprise value of around EUR 1.5 billion; Centor closed October 1, 2026, PPP is expected in Q1 2027.
Drug delivery capacity
FY2025 capex of EUR 122.7m in Plastics & Devices went to syringe capacity in Germany, Mexico and North Macedonia and plastics and medical systems capacity in North America; FY2026 capex covers injectors and pens in North America and the Czech Republic and syringes at Skopje and Queretaro.
Glass furnaces
FY2025 capex of EUR 177.0m in glass funded new furnaces at Lohr and Momignies and injection-vial capacity at Morganton; FY2026 includes tank rebuilds at Essen and Momignies.
Lower capex
Capex was EUR 149 million in nine months of 2026, 37% lower, about 40% base and 60% growth, and around 9% of sales for the year.

Challenges and risks

Debt and going-concern risk
Net financial debt was EUR 2,012.9m with leverage of 4.95x at end-FY2025; the auditor's going-concern uncertainty rested on selling Centor and refinancing, and a EUR 100.0m minimum-liquidity covenant applies.
Accounting restatement and BaFin
A BaFin audit over bill-and-hold revenue led to restating 2024 revenue down by EUR 44.6m; the investigation is ongoing with no timeline, and the share was excluded from the SDAX.
Weak glass businesses
Tubular Glass Europe and Moulded Glass remain the problems; Moulded Glass runs at EUR 80-85 million annualized EBITDA against an ambition of EUR 100 million and beyond.
Energy costs
Energy is a substantial cost in glass melting; it is about 80% hedged in 2026 but less than 50% for next year, a headwind for 2027.
Lost reverse factoring
Reverse-factoring lines were withdrawn after a worse credit rating, pushing free cash flow before M&A negative.

What leadership says

“This truly marks an inflection point for Gerresheimer, as this solves our too-high-debt burden.”

Wolf Lehmann, CFO · On the Centor and PPP sales, preliminary Q2 2026 results call, September 30, 2026

“The new Gerresheimer will be smaller in size, more focused, and higher in quality”

Achim Schalk, Member of the Management Board · Preliminary Q2 2026 results call, September 30, 2026

“Clearly, PPG performance is not at an acceptable level.”

Uwe Röhrhoff, Interim CEO · FY2025 results call, June 29, 2026

“our grow, fix, and sell portfolio strategy remains unchanged”

Wolf Lehmann, CFO · Preliminary Q3 2026 results call, October 30, 2026

Where a supplier can help

Procurement and cost programmes
The gto procurement and operations workstreams and the EUR 50-70 million EBITDA target open the door to suppliers that cut input, logistics or production costs with fast payback.
Energy hedging and efficiency
With less than 50% of next year's energy hedged and glass melting energy-intensive, energy procurement and furnace efficiency solutions tie directly to a stated headwind.
Drug delivery ramp-up
The Peachtree City ramp-up and syringe, injector and pen capacity for GLP-1 customers need automation, quality and validation support.
Finance, compliance and controls
The restatement, BaFin investigation, refinancing and divestments create demand for finance systems, internal controls and carve-out services.
Leaner SG&A
The more than 20% SG&A cut into 2027 suits shared-services, automation and productivity tools.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Gerresheimer?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Gerresheimer

What does Gerresheimer do?

Gerresheimer makes drug containment and delivery products for pharma, biotech and cosmetics customers, including syringes, pens, auto-injectors, inhalers, vials, cartridges, ampoules and glass and plastic bottles.

What is Gerresheimer's revenue?

FY2025 revenues were EUR 2,320.9m with adjusted EBITDA of EUR 384.0m. For FY2026 the company guides to revenue of EUR 2.3-2.35 billion.

How many employees does Gerresheimer have?

About 13,600 people at November 30, 2025, with companies consolidated from 17 countries.

Who leads Gerresheimer?

CFO Wolf Lehmann and Management Board member Achim Schalk lead as co-CEOs while the Supervisory Board decides on a permanent CEO; Uwe Röhrhoff was interim CEO from November 1, 2025.

What is Gerresheimer's strategy?

A grow, fix and sell portfolio strategy: grow drug delivery devices and syringes, fix Tubular Glass Europe and SG&A through the gto transformation, sell Centor and Primary Packaging Plastics to cut debt, and later divest Moulded Glass.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)